Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study

Journal of Clinical Oncology

Volumn 23, Issue 23, 2005, Pages 5294-5304

  Galanis, Evanthia ^a   Buckner, Jan C ^a   Maurer, Matthew J ^a   Kreisberg, Jeffrey I ^a   Ballman, Karla ^a   Boni, J ^a   Peralba, Josep M ^a   Jenkins, Robert B ^a   Dakhil, Shaker R ^a   Morton, Roscoe F ^a   Jaeckle, Kurt A ^a   Scheithauer, Bernd W ^a   Dancey, Janet ^a   Hidalgo, Manuel ^a   Walsh, Daniel J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; GADOLINIUM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; STEROID; TEMSIROLIMUS; ALKYLATING AGENT; DRUG DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG STRUCTURE; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN TUMOR; DISEASE FREE SURVIVAL; DRUG EFFECT; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTO ONCOGENE; SALVAGE THERAPY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-1; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; SALVAGE THERAPY; SIROLIMUS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 23944453425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.23.622     Document Type: Article

References (40)

1. Brandes AA, Fiorentino MV: The role of chemotherapy in recurrent malignant gliomas: An overview. Cancer Invest 14:551-559, 1996
2. Kornblith PL, Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68:1-17, 1988
3. Galanis E, Buckner J: Chemotherapy for high-grade gliomas. Br J Cancer 82:1371-1380, 2000
4. Tatter SB: Recurrent malignant glioma in adults. Curr Treat Options Oncol 3:509-524, 2002
5. Chang SM, Theodosopoulos P, Lamborn K, et al: Temozolomide in the treatment of recurrent malignant glioma. Cancer 100:605-611, 2004
6. Skotinicki JS, Leone CL, Smith AL, et al: Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779. AACR NCI EORTC Mol Targets Cancer Ther, 2001 (abstr 477)
7. Molnar-Kimber KL: Mechanism of action of rapamycin (Sirolimus, Rapamune). Transplant Proc 28:964-969, 1996
8. Brunn GJ, Hudson CC, Sekulic A, et al: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101, 1997
9. Gingras AC, Kennedy SG, O'Leary MA, et al: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12:502-513, 1998
10. Muise-Helmericks RC, Grimes HL, Bellacosa A, et al: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273:29864-29872, 1998
11. Seufferlein T, Rozengurt E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 56:3895-3897, 1996
12. Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926-1933, 2004
13. Hurtt MR, Moossy J, Donovan-Peluso M, et al: Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J Neuropathol Exp Neurol 51:84-90, 1992
14. Wang SI, Puc J, Li J, et al: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186, 1997
15. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001
16. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001
17. Leung LY, Liao K, Lim HK: CCI-779 (WAY-130779): Biotransformation in rat and human liver microsomes, and primarily characterization of cytochrome P450 isozyme(s) involved in its metabolism. Wyeth-Ayerst GTR 32279, 1998
18. Gibbons J, Petersen R, Lasota P, et al: The effect of WAY-130779 on the growth of human tumor cells in vitro. Wyeth-Ayerst GTR 32380, 1998
19. Discafani C: The effect of CCI-779 on the growth of human glioblastoma cells in nu/nu female mice. Wyeth-Ayerst GTR 32469, 1998
20. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347, 2004
21. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
22. Hess KR, Wong ET, Jaeckle KA, et al: Response and progression in recurrent malignant glioma. Neuro-oncol 1:282-288, 1999
23. Punt CJ, Boni J, Bruntsch U, et al: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937, 2003
24. Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA, Applied Therapeutics Inc, 1992, pp 1-43
25. Smith JS, Tachibana I, Passe SM, et al: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-1256, 2001
26. Jenkins RB, Qian J, Lieber MM, et al: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531, 1997
27. Malik SN, Brattain M, Ghosh PM, et al: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171, 2002
28. Kreisberg JI, Malik SN, Prihoda TJ, et al: Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232-5236, 2004
29. Malik SN, Bedolla RG, Dawson D, et al: Immunohistochemical detection of activated signaling proteins in colon cancer. Proc Am Assoc Cancer Res 402:2169, 2001
30. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
31. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004
32. Taha C, Liu Z, Jin J, et al: Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin: Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem 274:33085-33091, 1999
33. Huffman TA, Mothe-Satney I, Lawrence JC, Jr.: Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A 99:1047-1052, 2002
34. Galanis E, Maurer MJ, Ballman KV, et al: Validation of neuroradiologic response assessment in gliomas: RECIST (1D) vs 2D measurements vs computer-assisted tumor area vs volume., Proc ASCO, 2003, pp 106 (abstract 423)
35. Vos MJ, Hoekstra OS, Barkhof F, et al: Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 21:3559-3565, 2003
36. Hidalgo M, Rowinsky EK: The rapamycin-sensitive singal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686, 2000
37. Dudkin L, Diling MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764, 2001
38. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003
39. Eshleman JS, Carlson BL, Mladek AC, et al: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291-7297, 2002
40. Rao R, Sarkaria J, Frederick, et al: Synergistic inhibition of glioma cell growth upon combination therapy with the mTOR inhibitor rapamycin and the epidermal growth factor receptor inhibitor, EKI-785. Proc Am Assoc Cancer Res 44, 2003 (abstr 718)